<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123807</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0660</org_study_id>
    <nct_id>NCT05123807</nct_id>
  </id_info>
  <brief_title>Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)</brief_title>
  <official_title>Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to estimate overall survival after secondary cytoreductive surgery&#xD;
      and HIPEC for women with recurrent primary mucinous ovarian cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      The primary objective is to estimate progression-free survival (PFS) after secondary&#xD;
      cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
        -  To estimate overall survival (OS) after secondary cytoreductive surgery and HIPEC for&#xD;
           women with recurrent primary mucinous ovarian cancer&#xD;
&#xD;
        -  To evaluate toxicity and morbidity of secondary cytoreductive surgery and HIPEC for&#xD;
           women with recurrent primary mucinous ovarian cancer&#xD;
&#xD;
        -  To estimate quality of life after secondary cytoreductive surgery and HIPEC for women&#xD;
           with recurrent primary mucinous ovarian cancer&#xD;
&#xD;
        -  To estimate what proportion of patients who preoperatively appear to be candidates for&#xD;
           secondary cytoreductive surgery and HIPEC are found to have unresectable disease at time&#xD;
           of surgical exploration&#xD;
&#xD;
        -  To collect blood and tumor samples for biobanking to be used for exploratory endpoints&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2022</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate progression-free survival (PFS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer</measure>
    <time_frame>through study completion, an average of 6 years (patients will be followed for 6 years after treatment completion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Cytoreductive surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cytoreductive surgery</intervention_name>
    <description>(an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy</description>
    <arm_group_label>Cytoreductive surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed recurrent primary&#xD;
             mucinous ovarian cancer&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Prior to surgery, patients must have adequate organ and marrow function as defined&#xD;
             below (within 30 days of registration):&#xD;
&#xD;
               1. absolute neutrophil count &gt;1,500/mcL&#xD;
&#xD;
               2. platelets &gt;100,000/mcL&#xD;
&#xD;
               3. total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
               4. creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
               5. AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal&#xD;
&#xD;
          -  Patients must be &gt; 2 weeks from prior chemotherapy or radiation therapy&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
             (either directly or via a legally authorized representative)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are receiving concurrent investigational therapy or who have received&#xD;
             investigational therapy within 30 days of HIPEC (investigational therapy is defined as&#xD;
             treatment for which there is currently no regulatory authority approved indication)&#xD;
&#xD;
          -  Patients with mucinous tumors with pathologic confirmation of a non-gynecologic site&#xD;
             of origin&#xD;
&#xD;
          -  Patients with known active CNS metastases&#xD;
&#xD;
          -  Patients with known hypersensitivity to any of the components of cisplatin&#xD;
&#xD;
          -  Patients with a prior or concurrent malignancy who natural history or treatment does&#xD;
             not have the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are eligible for this trial.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Women who are pregnant or nursing women&#xD;
&#xD;
          -  Patients with peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  History of allogenic transplant&#xD;
&#xD;
          -  History of prior HIPEC or intraperitoneal chemotherapy&#xD;
&#xD;
          -  Known bulky extra-abdominopelvic disease&#xD;
&#xD;
          -  Patients with hearing impairment/tinnitus ≥ grade 2&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Frumovitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Frumovitz, MD</last_name>
    <phone>713-792-9599</phone>
    <email>mfrumovitz@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Frumovitz</last_name>
      <phone>713-792-9599</phone>
      <email>mfrumovitz@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Michael Frumovitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

